Cephalon Returns Lupuzor Rights to ImmuPharma
BioWorld International Correspondent
LONDON – ImmuPharma plc has pulled out of a $500 million cash deal for Lupuzor, over concerns that the lupus treatment would be beached following the acquisition of its licensee Cephalon Inc., by Teva Pharmaceutical Industries Ltd., which was finalized Oct. 14.
London-based ImmuPharma is now scouting for a new partner for the drug, which is ready for Phase III.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter